{"id":946,"date":"2024-08-06T15:29:08","date_gmt":"2024-08-06T07:29:08","guid":{"rendered":"https:\/\/flcube.com\/?p=946"},"modified":"2024-10-14T10:09:50","modified_gmt":"2024-10-14T02:09:50","slug":"biontech-ends-collaboration-with-genmab-on-acasunlimab-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=946","title":{"rendered":"BioNTech Ends Collaboration with Genmab on Acasunlimab Development"},"content":{"rendered":"\n

Genmab A\/S (NASDAQ: GMAB<\/a>), a Danish biotechnology company, has announced that its German partner BioNTech SE (NASDAQ: BNTX<\/a>) has opted to discontinue their collaboration on the development of the bispecific antibody (BsAb) acasunlimab. Acasunlimab, which targets the programmed death-ligand 1 (PD-L1) and 4-1BB pathways, was under joint development with both companies having initiated three clinical trials, including a recent Phase II study in non-small cell lung cancer patients who had received prior treatments. BioNTech’s decision to withdraw from the partnership is attributed to strategic portfolio considerations and not due to concerns over recent clinical data.<\/p>\n\n\n\n

With BioNTech’s exit, Genmab will assume full responsibility for the development of acasunlimab and is committed to making development and commercial milestone payments, as well as royalty payments, to BioNTech.<\/p>\n\n\n\n

The collaboration between Genmab and BioNTech, which began in 2015, focused on the discovery and development of antibodies. Genmab utilized its proprietary DuoBody technology platform, while BioNTech contributed its proprietary immunomodulatory antibodies. The two companies continue to collaborate on the development of GEN1053\/BNT313, a CD27 antibody, with development costs shared equally between them. Their ongoing partnership was reinforced by an expansion agreement signed in 2022.- Fineline.com<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Genmab A\/S (NASDAQ: GMAB), a Danish biotechnology company, has announced that its German partner BioNTech…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[342,368,1124,851],"class_list":["post-946","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-biontech","tag-genmab","tag-nasdaq-bntx","tag-nasdaq-gmab"],"yoast_head":"\nBioNTech Ends Collaboration with Genmab on Acasunlimab Development - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Genmab A\/S (NASDAQ: GMAB), a Danish biotechnology company, has announced that its German partner BioNTech SE (NASDAQ: BNTX) has opted to discontinue their collaboration on the development of the bispecific antibody (BsAb) acasunlimab. Acasunlimab, which targets the programmed death-ligand 1 (PD-L1) and 4-1BB pathways, was under joint development with both companies having initiated three clinical trials, including a recent Phase II study in non-small cell lung cancer patients who had received prior treatments. BioNTech's decision to withdraw from the partnership is attributed to strategic portfolio considerations and not due to concerns over recent clinical data.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=946\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioNTech Ends Collaboration with Genmab on Acasunlimab Development\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=946\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-06T07:29:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-14T02:09:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=946#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=946\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BioNTech Ends Collaboration with Genmab on Acasunlimab Development\",\"datePublished\":\"2024-08-06T07:29:08+00:00\",\"dateModified\":\"2024-10-14T02:09:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=946\"},\"wordCount\":203,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"BioNTech\",\"Genmab\",\"NASDAQ: BNTX\",\"NASDAQ: GMAB\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=946#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=946\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=946\",\"name\":\"BioNTech Ends Collaboration with Genmab on Acasunlimab Development - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-08-06T07:29:08+00:00\",\"dateModified\":\"2024-10-14T02:09:50+00:00\",\"description\":\"Genmab A\\\/S (NASDAQ: GMAB), a Danish biotechnology company, has announced that its German partner BioNTech SE (NASDAQ: BNTX) has opted to discontinue their collaboration on the development of the bispecific antibody (BsAb) acasunlimab. Acasunlimab, which targets the programmed death-ligand 1 (PD-L1) and 4-1BB pathways, was under joint development with both companies having initiated three clinical trials, including a recent Phase II study in non-small cell lung cancer patients who had received prior treatments. BioNTech's decision to withdraw from the partnership is attributed to strategic portfolio considerations and not due to concerns over recent clinical data.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=946#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=946\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=946#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioNTech Ends Collaboration with Genmab on Acasunlimab Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BioNTech Ends Collaboration with Genmab on Acasunlimab Development - Insight, China's Pharmaceutical Industry","description":"Genmab A\/S (NASDAQ: GMAB), a Danish biotechnology company, has announced that its German partner BioNTech SE (NASDAQ: BNTX) has opted to discontinue their collaboration on the development of the bispecific antibody (BsAb) acasunlimab. Acasunlimab, which targets the programmed death-ligand 1 (PD-L1) and 4-1BB pathways, was under joint development with both companies having initiated three clinical trials, including a recent Phase II study in non-small cell lung cancer patients who had received prior treatments. BioNTech's decision to withdraw from the partnership is attributed to strategic portfolio considerations and not due to concerns over recent clinical data.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=946","og_locale":"en_US","og_type":"article","og_title":"BioNTech Ends Collaboration with Genmab on Acasunlimab Development","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=946","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-08-06T07:29:08+00:00","article_modified_time":"2024-10-14T02:09:50+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=946#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=946"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BioNTech Ends Collaboration with Genmab on Acasunlimab Development","datePublished":"2024-08-06T07:29:08+00:00","dateModified":"2024-10-14T02:09:50+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=946"},"wordCount":203,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["BioNTech","Genmab","NASDAQ: BNTX","NASDAQ: GMAB"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=946#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=946","url":"https:\/\/flcube.com\/?p=946","name":"BioNTech Ends Collaboration with Genmab on Acasunlimab Development - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-08-06T07:29:08+00:00","dateModified":"2024-10-14T02:09:50+00:00","description":"Genmab A\/S (NASDAQ: GMAB), a Danish biotechnology company, has announced that its German partner BioNTech SE (NASDAQ: BNTX) has opted to discontinue their collaboration on the development of the bispecific antibody (BsAb) acasunlimab. Acasunlimab, which targets the programmed death-ligand 1 (PD-L1) and 4-1BB pathways, was under joint development with both companies having initiated three clinical trials, including a recent Phase II study in non-small cell lung cancer patients who had received prior treatments. BioNTech's decision to withdraw from the partnership is attributed to strategic portfolio considerations and not due to concerns over recent clinical data.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=946#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=946"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=946#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BioNTech Ends Collaboration with Genmab on Acasunlimab Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/946","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=946"}],"version-history":[{"count":3,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/946\/revisions"}],"predecessor-version":[{"id":5142,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/946\/revisions\/5142"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=946"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=946"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=946"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}